Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 10:29 PM
Ignite Modification Date:
2025-12-24 @ 10:29 PM
NCT ID:
NCT06225635
Brief Summary:
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab
Detailed Description:
Evaluate the Safety
1. Adverse Events
2. Concomitant Medications
3. Vital Signs
4. Laboratory Test
Pharmacokinetics
1. 1st Evaluation Variable: 1st Cmax, AUCt of Total Ezetimibe, Rosuvastatin
2. 2nd Evaluation Variable: AUC∞, Tmax, t1/2 of Total Ezetimibe, Rosuvastatin and Cmax, AUCt, AUC∞, Tmax, t1/2 of Free Ezetimibe
Study:
NCT06225635
Study Brief:
Protocol Section:
NCT06225635